Genmab data points to early bone cancer drug launch: analysts

COPENHAGEN (Reuters) - Positive results from a trial by Danish biotech company Genmab of its bone marrow cancer drug could lead to a launch as early as this year and it may become a blockbuster treatment earning $3.5 billion in annual revenues, analysts said.

via Reuters: Health News Read More Here..

For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com

Lake forest health and fitness http://ift.tt/1CYHgES